+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 65Years
All Genders
ID06880380

Phase 1 Study of CAR-T Cell Therapy for Treating HIV-1 Infection in Adults Aged 18 to 65

Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2026-03-05

3

Participants Needed

1

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of autologous CAR-T cell therapy in adults with HIV-1 infection who have been on regular antiviral treatment and have controlled viral levels. This Phase 1 study aims to assess the safety and potential for a functional cure in HIV-1AIDS patients by monitoring adverse reactions and viral RNA levels. Participants will receive an intravenous infusion of HIV-CAR-T cells, which are specially modified immune cells designed to target HIV. The study includes a treatment period followed by monitoring for up to 12 weeks after the CAR-T cell infusion to evaluate safety and viral response. During the study, participants will be closely monitored with laboratory tests including viral RNA measurements and immune cell counts. Safety assessments focus on the incidence of adverse reactions within 12 weeks post-infusion. Participants must comply with follow-up visits and study procedures over this period to help researchers understand the therapys effects and safety profile.

CONDITIONS

Brief Title

The Efficacy and Safety Study of CAR-T Cells for Functional Cure in HIV-1/AIDS Patients

Research Team

X

Xiao Wang, D.Eng

X

Xuanling Shi, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here